PHILADELPHIA, June 25/ PRNewswire-AsiaNet/ –
New data from a subgroup analysis of the A1chieve(R) study show that
intensifying treatment with NovoMix(R) 30 (Biphasic insulin aspart) can
significantly improve blood glucose control in people with type 2 diabetes with
a reduced incidence of hypoglycemia. The results were presented at the 72nd
Annual Scientific Sessions of the ADA in Philadelphia.
( Logo: http://photos.prnewswire.com/prnh/20120622/538522 )
The results were from a subgroup analysis of 1,033 patients who were first
treated with NovoMix(R) 30 twice-daily then intensified to three-times daily
over the 24-week study period. Before initiation with NovoMix(R) 30, the
average blood glucose control (HbA1c) among this subgroup of patients was 9.8%,
despite the fact that 80.6% were receiving oral glucose-lowering drugs. This
figure is well above the ADA recommended target of 7%. Poor blood glucose
control puts people at high risk of developing diabetes-related complications.
After 24 weeks of treatment with NovoMix(R) 30 there was a significant
reduction in HbA1c levels from 9.8% to 7.6% and in fasting plasma glucose from
204.5mg/dl to 128.20mg/dl. There were also significant reductions in
post-breakfast plasma glucose level from 261.6mg/dl to 165.20mg/dl. The overall
incidences of hypoglycaemia were reduced from 4.26 to 3.76 events/ person-year.
Commenting Professor Philip Home said: “The study shows that NovoMix(R) 30
is an effective option for type 2 diabetes patients for both insulin initiation
and intensification. Improvements in blood glucose control of this magnitude
are of significant clinical importance and are key for the long-term control of
the disease for the people involved”.
A1chieve(R) is the largest real-life study of insulin in type 2 diabetes
with 66,726 people from 28 countries across Asia, Africa, Europe and Latin
1. Khamseh M, Hasan I, Hussein Z et al. Experience of three-times-daily
biphasic insulin aspart in clinical practice: results from the
A1chieve study. Abstract presented at ADA 2012.
2. The UKPDS Group. Intensive blood-glucose control with sulphonylurea or
insulin compared with conventional treatment and risk of complications
in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
SOURCE: Novo Nordisk